The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Is venetoclax combined with low dose cytarabine and actinomycin D safe and effective in patients with AML who relapse after allo-HSCT?

Jul 16, 2020

During the 25th European Hematology Association (EHA) Annual Congress, the AML Hub spoke to Andrius Žučenka, Vilnius University Hospital Santaros Klinikos, Vilnius, LT. We asked, Is venetoclax + low dose cytarabine (ara-C) + actinomycin D safe and effective in patients with AML following relapse to allogeneic hematopoietic stem cell transplantation (allo-HSCT)?

Is venetoclax + low dose ara-C + actinomycin D safe and effective in patients with AML?

Venetoclax in combination with low dose ara-C has demonstrated modest results in patients who relapse after allo-HSCT, with median overall survival rates between 3–6 months. Overexpression of the anti-apoptotic protein, MCL-1, is believed to play a significant role in patient resistance to venetoclax.

This interview outlines the study evaluating the ability of actinomycin D, identified as having MCL-1 inhibiting properties, in combination with venetoclax + low dose ara-C to improve survival outcomes of patients with AML who relapse after allo-HSCT.